Developer docs
API playgroundTry for free, no card

Search company profiles

Destum Partners

Full company profile

uuid000erfe

Namestring
Destum Partners
Legal namestring
Destum Partners, Inc.
Company typeenum
Private
Founded yearint
2006
Descriptiontext

Destum Partners is a boutique advisory and consulting firm founded in 2006 and headquartered in Charlotte, North Carolina, serving biopharmaceutical and life sciences companies globally. The firm operates two integrated practices: an Advisory Practice that provides transaction advisory services including licensing agreements, asset acquisitions, and co-development arrangements (40+ transactions closed with cumulative deal value exceeding $5.25 billion), and a Consulting Practice powered by Σ dp Analytics, which delivers scientific, market, commercial, and financial expertise through product and market assessments and asset valuations using rNPV and DCF methodologies. Additional proprietary products include KOL CONTACT (a Key Opinion Leader database initially focused on U.S. oncology) and MediCalculate (a licensing terms benchmarking tool).

The firm is entirely owned by its three Managing Directors — Gareth Lugg (Co-Founder), Tom Filipczak, and Matthew Vanderberg — who collectively bring over 60 years of combined industry experience from prior roles at Morgan Stanley, Smith Barney, Pfizer, Roche, Novartis/Sandoz, Wachovia, and Bank of America. Destum Partners serves a clientele ranging from multinational Fortune 500 pharmaceutical companies to mid-sized and early-stage privately held biotechs, with operating geographies spanning the Americas, Europe, Asia, and Oceania.

Revenue is generated through transaction-based advisory fees (success fees on closed licensing and M&A deals) and professional-services consulting engagements, both delivered through a direct, senior-led engagement model. The firm employs approximately 9-12 people, operates without external venture or private equity backing, and markets primarily through industry conferences (BIO, Bio-Europe, JPM Healthcare), press releases on closed transactions, and its corporate website. It is selective in its client portfolio, positioning its integrated consulting-plus-advisory model as a differentiated value proposition in a sector where most competitors offer only one of the two services.

Short descriptiontext

Destum Partners is a privately held boutique advisory and consulting firm founded in 2006 in Charlotte, NC, providing integrated transaction advisory and strategic consulting services to biopharmaceutical and life sciences companies worldwide, having closed 40+ deals worth over $5.25 billion.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersCharlotte, United States
HQ citystring
Charlotte
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
biopharma advisory services, transaction advisory, licensing consulting, life sciences consulting, asset valuation services
Industry1 code
PRIMARYFSAEAGAJ
Industry-Specialist / Sector-Focused M&A Advisory
NAICS code2 codes
  • Management Consulting Services54161
  • Other Scientific and Technical Consulting Services54169
SIC code2 codes
  • Services-Management Consulting Services8742
  • Security Brokers, Dealers & Flotation Companies6211
Product category
Biopharmaceutical Advisory Services
No data
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model2 records
1Advisory Services
TypeTransaction Fee
Description

Advisory practice focused on transactions including licensing agreements, acquisitions, and partnerships. They have completed 40+ transactions worth over $5.25B. Deal types include licensing agreements, asset acquisitions, and co-development arrangements.

destumpartners.com
2Consulting Services
TypeProfessional Services
Description

Consulting services powered by Σ dp Analytics, providing scientific, market, commercial, and financial expertise. Services include Product & Market Assessments and Asset Valuations using methodologies such as rNPV and DCF.

destumpartners.com
Marketing channels3 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components3 values
Personnel, Operations, Marketing or Sales
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

Destum Partners provides strategic advisory and consulting services to biopharmaceutical and life sciences companies. The firm operates two integrated practices: an Advisory Practice that represents buyers or sellers in transactions (licensing agreements, acquisitions, co-development arrangements) and a Consulting Practice powered by Σ dp Analytics that delivers scientific, market, commercial, and financial expertise through product and market assessments and asset valuations.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 2 values shown
  • Completed over 42 transactions worth over $5.25B
+1 more record
Product overview1 text field

Destum Partners is a boutique advisory and consulting firm that offers two integrated service practices. The Advisory Practice provides transaction/deal advisory services for biopharma and life sciences companies, having completed over 42 transactions worth over $5.25B. The Consulting Practice, powered by Σ dp Analytics, delivers strategic consulting through product and market assessments and asset valuations using methodologies like rNPV and DCF. Additional products include KOL CONTACT (a Key Opinion Leader database) and MediCalculate (a licensing terms negotiation tool).

Product and service3 records
1Advisory Practice
CategoryTransaction Advisory
2Consulting Practice
CategoryStrategic Consulting
3KOL CONTACT
Scale indicator4 records

Each record includes

Type, Value, Description, Source

Partnership11 partners
Strategic tierFlagshipTypeStrategic or Co-development PartnerAnnounced on2026-02-23
Description

Destum Partners acted as transaction advisor to Quiver Bioscience in a multi-year collaboration and licensing agreement. Quiver will receive undisclosed advance payment plus milestone payments of up to $120 million and royalties. The partnership focuses on discovering and advancing novel therapeutics for Developmental and Epileptic Encephalopathies (DEEs), a group of rare genetic diseases causing severe treatment-resistant seizures in children.

Strategic tierNotableTypeStrategic or Co-development PartnerAnnounced on2026-02-01
Description

Destum Partners acted as transaction advisor to Quiver Bioscience in a research collaboration to advance novel gene-targeted therapeutic approach for Fragile X syndrome treatment. Combines Quiver's GPS platform with QurAlis' precision medicine expertise.

Strategic tierNotableTypeChannel Partner/ Reseller/ DistributorAnnounced on2026-01-08
Description

Destum Partners acted as exclusive advisor to Compai Pharma for exclusive licensing and distribution agreement to commercialize BINOSTO in Malaysia for osteoporosis treatment.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2023-09-25
Description

Destum Partners acted as transaction advisor to AcuraStem in a license agreement where Takeda received exclusive worldwide license to AcuraStem's PIKFYVE program. AcuraStem received upfront and milestone payments totaling up to approximately $580 million plus tiered royalties. The program focuses on a novel therapeutic target for ALS and TDP-43 proteinopathies.

Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2023-09-19
Description

Destum Partners acted as exclusive advisor to EffRx for an exclusive licensing and distribution agreement where Radius received rights to commercialize BINOSTO in the United States for osteoporosis treatment.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2023-03-27
Description

Destum Partners acted as transaction advisor to BIORCHESTRA in an exclusive research, option, and licensing agreement worth up to $861M for CNS-targeted polymeric nanoparticle delivery of nucleic acid therapies. Collaboration focuses on initial target with option to expand to several additional targets.

Strategic tierNotableTypeStrategic or Co-development PartnerAnnounced on2022-05-20
Description

Destum Partners acted as business development and licensing transaction advisor to Hovione in an exclusive global license agreement for JX08, a preclinical ophthalmology program. JIXING received global rights and leads full lifecycle from preclinical through commercialization.

Strategic tierNotableTypeStrategic or Co-development PartnerAnnounced on2022-01-04
Description

Destum Partners served as advisor to BIORCHESTRA in a research collaboration to develop miRNA-targeted therapeutics for epilepsy treatment. SK Biopharmaceuticals validates disease-modifying targets and conducts preclinical studies. Joint ownership of IP and licensing rights to discovered compounds.

Strategic tierNotableTypeStrategic or Co-development PartnerAnnounced on2021-11-15
Description

Destum Partners acted as business development advisor to Antios for acquiring IP rights to fourth-generation HBV capsid assembly modulators (CAMs) from Italian sellers/parties. Total potential value of up to $50 million plus royalties.

Strategic tierNotableTypeChannel Partner/ Reseller/ DistributorAnnounced on2021-01-12
Description

Destum Partners advised PAION on exclusive licensing agreement for GIAPREZA and XERAVA in Europe. La Jolla received $22.5 million upfront and up to $109.5 million in commercial milestones plus royalties (15% for XERAVA, 18-24% for GIAPREZA).

11Hammock Pharmaceuticals and Daré Bioscience
Strategic tierMinorTypeChannel Partner/ Reseller/ DistributorAnnounced on2018-12-06
Description

Destum Partners advised Hammock Pharmaceuticals on licensing sale of global rights to MP-101 for bacterial vaginosis treatment and underlying hydrogel drug delivery technology.

destumpartners.com
Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight4 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Boutique life sciences transaction advisory firm offering M&A, licensing, and strategic advisory to biopharma companies. Directly comparable to Destum Partners in target client (biotech and pharma), service mix (licensing and M&A advisory), and boutique scale.

TypeDirect peer
Description

Life sciences advisory firm focused on strategic transactions, licensing, and M&A for healthcare and biotech clients. Comparable in mandate type, target market, and boutique positioning.

TypeDirect peer
Description

Healthcare and life sciences M&A advisory firm serving pharma, biotech, and specialty companies. Highly comparable in sector focus and deal-driven advisory model.

TypeDirect peer
Description

Boutique life sciences consulting and advisory firm providing strategic, transactional, and valuation services to biopharma. Closely comparable to Destum in integrated consulting-plus-advisory model and therapeutic-area-agnostic positioning.

TypeDirect peer
Description

Life sciences strategy consulting firm serving pharma, biotech, and medtech on market assessments, valuations, and transaction support. Comparable in consulting-side offerings (Product & Market Assessments, Asset Valuations) using methodologies like rNPV.

TypeDirect peer
Description

Life sciences consulting firm focused on commercial strategy, market assessment, and transaction support for biotech and pharma. Comparable in therapeutic-area breadth, scientific rigor, and boutique client-service model.

TypeBroad incumbent
Description

Global management consulting firm with a significant life sciences practice covering strategy, M&A, and licensing. Comparable in serving biopharma advisory and consulting needs but operates at much larger scale and offers a broader portfolio of services.

TypeDirect peer
Description

Life sciences-focused investment bank advising biotech and pharma on M&A, licensing, and financing. Comparable in boutique deal advisory model and mid-market biopharma client base.

TypeEmerging player
Description

Life sciences consulting firm offering commercial, scientific, and strategic advice to biotech and pharma. Comparable in boutique consulting-plus-advisory positioning but smaller scale.

10Trinity Partners
TypeDirect peer
Description

Life sciences consulting firm providing strategy, transaction, and commercial advisory to biotech and pharma companies. Comparable in therapeutic-area-agnostic consulting and advisory model.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers16 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles1 record

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Destum Partners

Biopharmaceutical Advisory Servicesdestumpartners.com

Destum Partners is a privately held boutique advisory and consulting firm founded in 2006 in Charlotte, NC, providing integrated transaction advisory and strategic consulting services to biopharmaceutical and life sciences companies worldwide, having closed 40+ deals worth over $5.25 billion.

What Destum Partners does

Destum Partners is a boutique advisory and consulting firm founded in 2006 and headquartered in Charlotte, North Carolina, serving biopharmaceutical and life sciences companies globally. The firm operates two integrated practices: an Advisory Practice that provides transaction advisory services including licensing agreements, asset acquisitions, and co-development arrangements (40+ transactions closed with cumulative deal value exceeding $5.25 billion), and a Consulting Practice powered by Σ dp Analytics, which delivers scientific, market, commercial, and financial expertise through product and market assessments and asset valuations using rNPV and DCF methodologies. Additional proprietary products include KOL CONTACT (a Key Opinion Leader database initially focused on U.S. oncology) and MediCalculate (a licensing terms benchmarking tool).

The firm is entirely owned by its three Managing Directors — Gareth Lugg (Co-Founder), Tom Filipczak, and Matthew Vanderberg — who collectively bring over 60 years of combined industry experience from prior roles at Morgan Stanley, Smith Barney, Pfizer, Roche, Novartis/Sandoz, Wachovia, and Bank of America. Destum Partners serves a clientele ranging from multinational Fortune 500 pharmaceutical companies to mid-sized and early-stage privately held biotechs, with operating geographies spanning the Americas, Europe, Asia, and Oceania.

Revenue is generated through transaction-based advisory fees (success fees on closed licensing and M&A deals) and professional-services consulting engagements, both delivered through a direct, senior-led engagement model. The firm employs approximately 9-12 people, operates without external venture or private equity backing, and markets primarily through industry conferences (BIO, Bio-Europe, JPM Healthcare), press releases on closed transactions, and its corporate website. It is selective in its client portfolio, positioning its integrated consulting-plus-advisory model as a differentiated value proposition in a sector where most competitors offer only one of the two services.

Destum Partners firmographics

Firmographics
Name
Destum Partners
Legal name
Destum Partners, Inc.
Website
https://destumpartners.com
Company type
Private
Founded year
2006
Operating status
Operating
Headcount range
1–10 employees
Short description
Destum Partners is a privately held boutique advisory and consulting firm founded in 2006 in Charlotte, NC, providing integrated transaction advisory and strategic consulting services to biopharmaceutical and life sciences companies worldwide, having closed 40+ deals worth over $5.25 billion.
Ownership category
akta.pro rank

Destum Partners industry classification

Industry
Product category
Biopharmaceutical Advisory Services
NAICS
Management Consulting Services (54161), Other Scientific and Technical Consulting Services (54169)
SIC
Services-Management Consulting Services (8742), Security Brokers, Dealers & Flotation Companies (6211)
akta.pro industry
PRIMARYFSAEAGAJ
Industry-Specialist / Sector-Focused M&A Advisory

Keywords

  • Biopharma advisory services
  • Transaction advisory
  • Licensing consulting
  • Life sciences consulting
  • Asset valuation services

Where Destum Partners is headquartered

Location

Headquarters

HQ city
Charlotte
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Destum Partners business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Operations, Marketing or Sales

Revenue model

  1. Advisory Services: Advisory practice focused on transactions including licensing agreements, acquisitions, and partnerships. They have completed 40+ transactions worth over $5.25B. Deal types include licensing agreements, asset acquisitions, and co-development arrangements.
  2. Consulting Services: Consulting services powered by Σ dp Analytics, providing scientific, market, commercial, and financial expertise. Services include Product & Market Assessments and Asset Valuations using methodologies such as rNPV and DCF.

Go-to-market motion2 records

Distribution channels1 record

Marketing channels3 records

Destum Partners product offering

Product offering

Core offering

Destum Partners provides strategic advisory and consulting services to biopharmaceutical and life sciences companies. The firm operates two integrated practices: an Advisory Practice that represents buyers or sellers in transactions (licensing agreements, acquisitions, co-development arrangements) and a Consulting Practice powered by Σ dp Analytics that delivers scientific, market, commercial, and financial expertise through product and market assessments and asset valuations.

Product overview

Destum Partners is a boutique advisory and consulting firm that offers two integrated service practices. The Advisory Practice provides transaction/deal advisory services for biopharma and life sciences companies, having completed over 42 transactions worth over $5.25B. The Consulting Practice, powered by Σ dp Analytics, delivers strategic consulting through product and market assessments and asset valuations using methodologies like rNPV and DCF. Additional products include KOL CONTACT (a Key Opinion Leader database) and MediCalculate (a licensing terms negotiation tool).

Differentiator

Problem solved

Functional benefit

Products and services

  • Advisory Practice
  • Consulting Practice
  • KOL CONTACT

Quantifiable outcome

  • Completed over 42 transactions worth over $5.25B
  • +1 more outcomes

Companies that use Destum Partners

Customer profile

Named customers16 records

Segments4 records

Ideal customer profiles2 records

Destum Partners technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Destum Partners partnerships and signals

Strategic signal

Partnerships

Eleven partnerships are on record, tiered flagship, notable, core and minor.

  • Angelini Pharma and Quiver BioscienceflagshipStrategic or Co-development Partner · 23 February 2026Destum Partners acted as transaction advisor to Quiver Bioscience in a multi-year collaboration and licensing agreement. Quiver will receive undisclosed advance payment plus milestone payments of up to $120 million and royalties. The partnership focuses on discovering and advancing novel therapeutics for Developmental and Epileptic Encephalopathies (DEEs), a group of rare genetic diseases causing severe treatment-resistant seizures in children.
  • Quiver Bioscience and QurAlisnotableStrategic or Co-development Partner · 1 February 2026Destum Partners acted as transaction advisor to Quiver Bioscience in a research collaboration to advance novel gene-targeted therapeutic approach for Fragile X syndrome treatment. Combines Quiver's GPS platform with QurAlis' precision medicine expertise.
  • EffRx Pharmaceuticals and Compai PharmanotableChannel Partner/ Reseller/ Distributor · 8 January 2026Destum Partners acted as exclusive advisor to Compai Pharma for exclusive licensing and distribution agreement to commercialize BINOSTO in Malaysia for osteoporosis treatment.
  • AcuraStem and TakedacoreStrategic or Co-development Partner · 25 September 2023Destum Partners acted as transaction advisor to AcuraStem in a license agreement where Takeda received exclusive worldwide license to AcuraStem's PIKFYVE program. AcuraStem received upfront and milestone payments totaling up to approximately $580 million plus tiered royalties. The program focuses on a novel therapeutic target for ALS and TDP-43 proteinopathies.
  • EffRx Pharmaceuticals and Radius HealthcoreChannel Partner/ Reseller/ Distributor · 19 September 2023Destum Partners acted as exclusive advisor to EffRx for an exclusive licensing and distribution agreement where Radius received rights to commercialize BINOSTO in the United States for osteoporosis treatment.
  • BIORCHESTRA and Global Biopharma CompanycoreStrategic or Co-development Partner · 27 March 2023Destum Partners acted as transaction advisor to BIORCHESTRA in an exclusive research, option, and licensing agreement worth up to $861M for CNS-targeted polymeric nanoparticle delivery of nucleic acid therapies. Collaboration focuses on initial target with option to expand to several additional targets.
  • Hovione and JIXINGnotableStrategic or Co-development Partner · 20 May 2022Destum Partners acted as business development and licensing transaction advisor to Hovione in an exclusive global license agreement for JX08, a preclinical ophthalmology program. JIXING received global rights and leads full lifecycle from preclinical through commercialization.
  • BIORCHESTRA and SK BiopharmaceuticalsnotableStrategic or Co-development Partner · 4 January 2022Destum Partners served as advisor to BIORCHESTRA in a research collaboration to develop miRNA-targeted therapeutics for epilepsy treatment. SK Biopharmaceuticals validates disease-modifying targets and conducts preclinical studies. Joint ownership of IP and licensing rights to discovered compounds.
  • Antios Therapeutics and IRBM/INGM/OSRnotableStrategic or Co-development Partner · 15 November 2021Destum Partners acted as business development advisor to Antios for acquiring IP rights to fourth-generation HBV capsid assembly modulators (CAMs) from Italian sellers/parties. Total potential value of up to $50 million plus royalties.
  • PAION AG and La Jolla PharmaceuticalnotableChannel Partner/ Reseller/ Distributor · 12 January 2021Destum Partners advised PAION on exclusive licensing agreement for GIAPREZA and XERAVA in Europe. La Jolla received $22.5 million upfront and up to $109.5 million in commercial milestones plus royalties (15% for XERAVA, 18-24% for GIAPREZA).
  • Hammock Pharmaceuticals and Daré BioscienceminorChannel Partner/ Reseller/ Distributor · 6 December 2018Destum Partners advised Hammock Pharmaceuticals on licensing sale of global rights to MP-101 for bacterial vaginosis treatment and underlying hydrogel drug delivery technology.

Scale indicators4 records

Recent moves6 records

Expansion highlights4 records

Destum Partners competitors and assessment

Company assessment

Direct peers

  • Locust Walk: Boutique life sciences transaction advisory firm offering M&A, licensing, and strategic advisory to biopharma companies. Directly comparable to Destum Partners in target client (biotech and pharma), service mix (licensing and M&A advisory), and boutique scale.
  • Outcome Capital: Life sciences advisory firm focused on strategic transactions, licensing, and M&A for healthcare and biotech clients. Comparable in mandate type, target market, and boutique positioning.
  • Torreya Partners: Healthcare and life sciences M&A advisory firm serving pharma, biotech, and specialty companies. Highly comparable in sector focus and deal-driven advisory model.
  • Back Bay Life Science Advisors: Boutique life sciences consulting and advisory firm providing strategic, transactional, and valuation services to biopharma. Closely comparable to Destum in integrated consulting-plus-advisory model and therapeutic-area-agnostic positioning.
  • Health Advances: Life sciences strategy consulting firm serving pharma, biotech, and medtech on market assessments, valuations, and transaction support. Comparable in consulting-side offerings (Product & Market Assessments, Asset Valuations) using methodologies like rNPV.
  • ClearView Healthcare Partners: Life sciences consulting firm focused on commercial strategy, market assessment, and transaction support for biotech and pharma. Comparable in therapeutic-area breadth, scientific rigor, and boutique client-service model.
  • Aquilo Partners: Life sciences-focused investment bank advising biotech and pharma on M&A, licensing, and financing. Comparable in boutique deal advisory model and mid-market biopharma client base.
  • Trinity Partners: Life sciences consulting firm providing strategy, transaction, and commercial advisory to biotech and pharma companies. Comparable in therapeutic-area-agnostic consulting and advisory model.

Broad incumbents

  • L.E.K. Consulting: Global management consulting firm with a significant life sciences practice covering strategy, M&A, and licensing. Comparable in serving biopharma advisory and consulting needs but operates at much larger scale and offers a broader portfolio of services.

Emerging players

  • Alacrita Consulting: Life sciences consulting firm offering commercial, scientific, and strategic advice to biotech and pharma. Comparable in boutique consulting-plus-advisory positioning but smaller scale.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat5 records

Key risks5 records

Key highlights6 records

Customer concentration

Destum Partners financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Destum Partners leadership team

Management profile

Number of profiles

Profiles1 record

Destum Partners funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Destum Partners M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Destum Partners

What does Destum Partners do?

Destum Partners provides strategic advisory and consulting services to biopharmaceutical and life sciences companies. The firm operates two integrated practices: an Advisory Practice that represents buyers or sellers in transactions (licensing agreements, acquisitions, co-development arrangements) and a Consulting Practice powered by Σ dp Analytics that delivers scientific, market, commercial, and financial expertise through product and market assessments and asset valuations.

Is Destum Partners a public or private company?

Destum Partners is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was Destum Partners founded?

Destum Partners was founded in 2006. It employs 1 to 10 people.

Where is Destum Partners based?

Destum Partners is headquartered in Charlotte, United States, in the North America region.

How does Destum Partners make money?

Two revenue lines are on record. Advisory Services are the primary driver. The others are consulting Services.

Who are Destum Partners's main competitors?

Direct peers on record are Locust Walk, Outcome Capital, Torreya Partners, Back Bay Life Science Advisors, Health Advances, ClearView Healthcare Partners, Aquilo Partners and Trinity Partners. L.E.K. Consulting is listed as a broad incumbent. Alacrita Consulting is listed as an emerging player.

Does Destum Partners have an API?

No public API is recorded for Destum Partners.

What industry is Destum Partners in?

Destum Partners's product category is Biopharmaceutical Advisory Services. Its primary akta.pro industry code is FSAEAGAJ, Industry-Specialist / Sector-Focused M&A Advisory. Its NAICS code is 54161 and its SIC code is 8742.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Stock TitanVyome posts 2025 results, cash runway to mid-2027Vyome Holdings, Inc. reported transformational 2025 results following a streamlined Nasdaq listing completed through a merger transaction, marking the company's first annual reporting period as a public company. The company's lead program VT-1953 delivered positive final Phase 2 results for treating symptoms of malignant fungating wounds, with an independent valuation by Destum Partners valuing the asset at approximately $1 billion after successful pivotal study, while the company maintains a clean capital structure with no debt or preferred stock and a cash runway expected through mid-2027.Investing.comVyome stock soars after analyst values lead drug candidate at $1 billion By Investing.comVyome stock surged 70% on Tuesday after an independent analysis by Destum Partners valued the company's lead drug candidate VT-1953 at $1 billion upon successful completion of Phase 3 studies. The analysis assessed VT-1953, a treatment for malignant fungating wounds—a rare complication of advanced solid tumors—projecting peak annual U.S. sales of $600 million and estimating the total addressable U.S. market at $2.2 billion, with no FDA-approved drugs currently existing for the condition. Vyome stated the analysis provides external validation as it works to advance VT-1953 toward pivotal development.Business Wire BlogIndependent Analyst Values Vyome’s VT-1953 at USD 1 Billion Upon Successful Completion of Phase 3 StudyVyome Holdings announced findings from an independent market assessment commissioned from Destum Partners, evaluating its lead clinical candidate VT-1953 for treating malignant fungating wounds (MFW), a rare complication of advanced solid tumors with no approved therapies. The analysis estimates the total addressable pharmacologic market in the US at approximately USD 2.2 billion, with projected peak annual net sales of USD 600 million and a risk-adjusted asset value of USD 455 million currently, potentially approaching USD 1 billion upon successful Phase 3 completion. Vyome CEO Venkat Nelabhotla stated the analysis provides external validation as the company seeks to advance VT-1953 toward pivotal development.GlobeNewswireRevelation Biosciences Inc. Engages Destum Partners Inc. to Identify Strategic Partners for REVTx-99 (Ex-US) and REVTx-200 (Worldwide)Revelation Biosciences engaged Destum Partners to find an Ex-US development partner for REVTx-99 and worldwide partners for REVTx-200. Both products target respiratory viral infections, with REVTx-99 planned for a phase 1 study in Q4 2021 and phase 2 in Q1 2022.GlobeNewswireDovitinib regulatory strategy confirmed and new combination biomarker DRP PD1/PD-L1 + dovitinib developed. Oncology Venture engages in partnering activities with Destum PartnersOncology Venture confirmed its regulatory strategy to submit a new drug application to the FDA for dovitinib approval in renal cancer, based on Novartis data. The company also completed development of the combination biomarker PD1-PD-L1/Dovitinib DRP, and appointed Destum Partners to support out-licensing activities.PR NewswireGRDG Sciences Concludes First Round of Research Achieving Objectives Resulting in a Valuation Exceeding $500 MillionGlobal Research & Discovery Group Sciences (GRDG) announced it has completed its initial cancer research objectives for a universal therapeutic drug platform, resulting in a valuation exceeding $500 million from independent IP valuation firm Destum Partners. The company, which was seeded with less than $2 million in research funding, developed multiple product candidates including Linebacker for broad-spectrum therapeutic applications, 3F mosquito control technology, Equivir/Nemovir for viral prophylaxis, and Sweet Sense as a low-glycemic sugar alternative. GRDG is now advancing into the next phase of research targeting neurological, anti-microbial, anti-viral, and oncology treatments.GlobeNewswireCellceutix Corporation Selects Destum Partners to Partner Psoriasis CompoundCellceutix selected Destum Partners to find a development partner for its psoriasis compound KM-133, which reduced psoriasis more than controls in an animal model. The psoriasis market is projected at $2.5 billion in 2008, growing 3.4% annually through 2018. KM-133 may qualify for an abridged FDA approval process.